JANX
Janux Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About JANX
Janux Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing immunotherapies for cancer
10955 Vista Sorrento Parkway, Suite 200, San Diego, California, 92130
--
Janux Therapeutics, Inc., was incorporated in Delaware on June 27, 2017. The Company is an innovative biopharmaceutical company developing next-generation therapies based on the Company's proprietary Tumor-Activated T-Cell Enginator (TRACTr) platform technology to better treat cancer patients. The company's initial focus is to develop a new class of T-cell adapters (TCE), and the company's main product candidates are designed for clinically validated drug targets.
Company Financials
EPS
JANX has released its 2025 Q3 earnings. EPS was reported at -0.39, versus the expected -0.61, beating expectations. The chart below visualizes how JANX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
JANX has released its 2025 Q3 earnings report, with revenue of 10.00M, reflecting a YoY change of 2177.90%, and net profit of -24.31M, showing a YoY change of 13.35%. The Sankey diagram below clearly presents JANX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
